Clinical Trial Update: Targeted Therapy With Glycogen Synthase Kinase-3 Inhibition for Arrhythmogenic Cardiomyopathy [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating a glycogen synthase kinase-3 inhibitor as a targeted therapy for arrhythmogenic cardiomyopathy, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Arrhythmogenic Cardiomyopathy
• Arrhythmogenic Right Ventricular Cardiomyopathy

Drugs mentioned

• Glycogen synthase kinase-3 inhibitor (GSK-3 inhibitor)

Snippet

Sponsor: Hamilton Health Sciences Corporation | Conditions: Arrhythmogenic Cardiomyopathy, Arrhythmogenic Right Ventricular Cardiomyopathy | Phase 2 | Status: RECRUITING